Drugs / Human tetanus immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06939777 Comparator | Apr → Dec 2025 | tetanus | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human tetanus immunoglobulin | “Human tetanus immunoglobulin(HTIG)” NCT06939777 ↗ |
| Known as | HTIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06939777 ↗ |
| Modality | Protein / enzyme biologic | “Human tetanus immunoglobulin(HTIG)” NCT06939777 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT06939777 ↗ |